跳转至内容
Merck
CN

D7275

Supelco

丙吡胺

别名:

双异丙吡胺

登录查看公司和协议定价

关于此项目

经验公式(希尔记法):
C21H29N3O
CAS Number:
分子量:
339.47
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

技术

HPLC: suitable
gas chromatography (GC): suitable

包装形式

neat

储存温度

2-8°C

SMILES字符串

CC(C)N(CCC(C(N)=O)(c1ccccc1)c2ccccn2)C(C)C

InChI

1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)

InChI key

UVTNFZQICZKOEM-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

应用

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

生化/生理作用

IA 类抗心律失常药;钠通道阻断剂

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

S Y Kim et al.
Drug safety, 5(6), 393-420 (1990-11-01)
Quinidine, procainamide and disopyramide are antiarrhythmic drugs in the class 1A category. These drugs have a low toxic to therapeutic ratio, and their use is associated with a number of serious adverse effects during long term therapy and life-threatening sequelae
R N Brogden et al.
Drugs, 34(2), 151-187 (1987-08-01)
Disopyramide is a widely used class IA antiarrhythmic drug with a pharmacological profile of action similar to that of quinidine and procainamide. Over the past 10 years disopyramide has demonstrated its efficacy in ventricular and atrial arrhythmias. In therapeutic trials
Annerie M E Moers et al.
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 14(3), 426-430 (2011-09-22)
Patients undergo ablation for focal atrial fibrillation (AF) as a result of failure of anti-arrhythmic drugs. Our basic studies have implicated cholinergic and adrenergic neurotransmitter release as the underlying mechanism for focal AF. Therefore, we tested the efficacy of a
Procainamide and disopyramide.
C Ribeiro et al.
European heart journal, 8 Suppl A, 11-19 (1987-03-01)
M S Croxson et al.
The New Zealand medical journal, 100(827), 407-408 (1987-07-08)
A patient treated with disopyramide presented with hypoglycaemia, a raised serum insulin level and died of pneumonia. From these findings and a review of 10 case reports, we propose that disopyramide causes hypoglycaemia by stimulation of insulin release as described

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持